Strategic partnerships Certest Biotec actively engages in multi-year collaborations with industry players (CordenPharma, Pro-Lab Diagnostics, Emervax, Circio) and has launched new products (Certest Resist CARBAS). Sales opportunities exist in expanding co-developed diagnostics, LNP lipid research collaborations, and distribution partnerships across regions.

Diversified divisions With four divisions—Raw Materials, Immunodiagnostics, VIASURE molecular kits, and Pharma—Certest offers end-to-end capabilities from materials supply to nucleic acid tests and RNA-based therapies. Cross-sell opportunities include supplying raw materials to in-house assay development and offering integrated molecular diagnostics for labs upgrading workflows.

RNA and LNP focus Strategic emphasis on RNA technologies, delivery systems, vaccines, and ionizable lipids for lipid nanoparticle formulations presents upsell potential in contract development and manufacturing, especially for clients pursuing RNA therapeutics and advanced vaccine platforms.

Global market momentum Recent CE IVDR certification for Certest Resist CARBAS and international partnerships indicate growing regulatory and distribution readiness. This creates opportunities to target regional distributors and healthcare networks seeking certified, ready-to-markets tests and integrated diagnostics.

Scalable capabilities A workforce exceeding 300 specialists and capabilities in protein expression, monoclonal antibody development, primers and probes manufacturing, and rapid diagnostics position Certest as a scalable partner for custom assay development, manufacturing contracts, and reagent supply for high-throughput labs.